EpCAM
Navigation Links
EpCAM in Medical News
Micromet, Inc. Reports Second Quarter 2009 Financial Results
...n 1.0] was 38% in patients with high expression of epcam (n=8), the target of adecatumumab, compared to 9% in patients with low epcam expression (n=11). Patients treated with higher do...clonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with ...Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...Micromet, Inc. Reports First Quarter 2009 Financial Results
... The data indicate that only cancer cells have an active signaling form of epcam that promotes tumor formation. This data further supports the scientific a...umors. Its human monoclonal antibody adecatumumab, or MT201, also binds to epcam and is being developed under a collaboration with Merck Serono. The current...Micromet, Inc. Reports Second Quarter 2008 Financial Results
...antibody targeting MCSP with potential use in the treatment of melanoma. -- Animal data suggested a therapeutic window for a BiTE antibody targeting epcam in a relevant animal species. Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "We have made s...Micromet, Inc. Reports First Quarter 2008 Financial Results
...eting MCSP with potential use in the treatment of melanoma. -- Animal data suggest a therapeutic window of a BiTE antibody targeting epcam in a relevant animal species. -- In March, Micromet established a scientific advisory board and named five leading oncology and immunology resear......ddition to current studies of MT103, three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. BiTE is a registe...age antibody is adecatumumab (MT201), a human monoclonal antibody targeting epcam expressing tumors. Adecatumumab is being developed by Micromet in collabora...
Micromet's BiTE(R) Antibodies Reveal Unique Mode of Action
...ced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. About Micromet, In...age antibody is adecatumumab (MT201), a human monoclonal antibody targeting epcam expressing tumors. Adecatumumab is being developed by Micromet in collabora......has provided proof-of-concept in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. About MT103 (MEDI-538) MT103, which is being co-developed with MedImmune as MEDI-538, is a B...
EpCAM in Medical Technology
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
...is found in approximately 35 to 40 percent of patients with this disease. "Given that more than 95 percent of colon cancer patients strongly express epcam on their tumors, and that 35 to 40 percent of patients who have a KRAS mutant tumor may not benefit from treatment with anti-EGFR antibodies, adecatum...
...ome for breast cancer patients with high epcam expression BETHESDA, Md., Sept. 15 /PRNewswire-F...igh EpCAM expression compared to patients with low epcam expression(2). The ongoing phase 1b clinical tri...as no responses were detected in patients with low epcam expression (0 of 8 patients). "These data demons...
...19, and has provided proof-of-concept in an ongoing phase 1 clinical trial in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
...ch (AACR) demonstrated MT110 can direct T cells to eliminate EpCAM-expressing human colorectal cancer stem cells in cell culture and in animal models. epcam is a target antigen that is highly and frequently expressed on many types of solid tumors. MT110 currently is in a phase 1 dose-escalating clinical t...Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
...ignificant room for improvement in these patients. epcam is a cancer target which is highly expressed in co...pressed target antigen on colorectal cancer cells, epcam has recently been shown to drive tumor growth and ...ancer. In this trial, patients with high levels of epcam expression, in a dose-dependent fashion, developed......is found in approximately 35 to 40 percent of patients with this disease. "Given that more than 95 percent of colon cancer patients strongly express epcam on their tumors, and that 35 to 40 percent of patients who have a KRAS mutant tumor may not benefit from treatment with anti-EGFR antibodies, adecatum...
...ome for breast cancer patients with high epcam expression BETHESDA, Md., Sept. 15 /PRNewswire-F...igh EpCAM expression compared to patients with low epcam expression(2). The ongoing phase 1b clinical tri...as no responses were detected in patients with low epcam expression (0 of 8 patients). "These data demons...
...19, and has provided proof-of-concept in an ongoing phase 1 clinical trial in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
EpCAM in Biological Technology
Findings Support Development of Micromet's EpCAM-specific Antibody Therapeutics
BETHESDA, Md., Jan. 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune d...
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
...he epithelial cell adhesion molecule, or EpCAM, a target antigen that is highly and frequently expressed on the surface of many types of solid tumors. epcam also has been shown to be expressed on cancer stem cells (2) and to promote tumor formation (3). The data presented at AACR show that the BiTE antibod...
Micromet Closes $80.5 Million Public Offering of Common Stock
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com......cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
Micromet Announces Pricing of Public Offering of Common Stock
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...Micromet Announces Public Offering of Common Stock
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com......cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
Micromet Added to Russell 3000 Index
...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com......cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
... in breast cancer patients with high expression of epcam ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ ...n 1.0] was 38% in patients with high expression of epcam (n=8), the target of adecatumumab, compared to 9% in patients with low epcam expression (n=11). Patients treated with higher do......he epithelial cell adhesion molecule, or EpCAM, a target antigen that is highly and frequently expressed on the surface of many types of solid tumors. epcam also has been shown to be expressed on cancer stem cells (2) and to promote tumor formation (3). The data presented at AACR show that the BiTE antibod...
EpCAM in Biological Products
CELLection Epithelial Enrich from Dynal Biotech
Description:... The kit contains 5 ml CELLection Dynabeads (4.5 m) coated with the monoclonal antibody against the human epithelial antigen epcam and DNase Releasing Buffer. For up to 5 log enrichment of epithelial tumour cells directly from blood, bone marrow or MNC. Tumour cells clumps can be...Company:Dynal Biotech
Dynabeads Epithelial Enrich from Dynal Biotech
Description:... The product contains 5 ml Dynabeads® (4.5 μm) coated with the monoclonal BerEP4 against the human epithelial antigen, epcam (epithelial cell adhesion molecule). Also available in 40 samples of 2 x 10e7 MNC in 1 ml volume (contains 1 ml Dynabeads®, Cat.No 161.01)...Company:Dynal Biotech
Other TagsOther Contentsminisatelliterepairrepairrepairrepairrepairrepairrepairrepairrepairmismatchmismatchmismatchmismatchmismatchmitochondriamitochondriamitochondriamitochondriamitochondriamitochondrialmitochondrialmitochondrialmitochondrialmitochondrialmitochondrialmitochondrialmitochondrialmodificationmodificationmodificationmodificationmodificationmodificationmodification
CoolGardStatscanMicropunctureIntradynKELLERValvelessJomedPINNACLEAvanti+TAXUSLauncherWiseguideConvoyPreface
(Date:11/26/2009)...J., Nov. 27 The diabetes populatio... next 25 years and annual medical spending on the ...$113 billion today, according to a study published...tional Changing Diabetes ® Program (NCDP), a...s by a team from the University of Chicago. ,, ...
(Date:11/26/2009)...rug tetrathiomolybdate (TM) has been shown in stud...ease, a disease caused by an overload of copper, a... Very little, however, is known about how the drug... by Northwestern University researchers now has pr...tructure of TM bound to copper-loaded metallochape...
(Date:11/26/2009)...en on an emotional rollercoaster, study finds , ...ll it the fear factor meets the jubilant sports fa...pecially those who root for the winning team -- en...ntested match and victory was in doubt, producing ...hat this Thanksgiving weekend as you,re glued to t...
(Date:11/26/2009)...r. David Kim of the Live Life Again Center, a prac...one of a growing number of physicians who are tak...o connect with individuals who are interested in s...ity. Dr. Kim is utilizing Facebook to share before...ce with the community. , ...
(Date:11/26/2009)...enton Communications announces a highly effective ...ilers struggling to make an economic recovery. , ...-- Flu fears is the type of challenge that could s...cording to Dr. David Benton, business growth exper... system – The Rfactor Intensive . “...
Breaking Medicine News(10 mins):Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Pharmacist Injects Cure for Ailing Businesses 2[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows[1] Research sheds light on workings of anti-cancer drug[0] Watching the Nail-Biting Big Game Hurts So Good[1] Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients[1] Pharmacist Injects Cure for Ailing Businesses
(Date:11/24/2009)...c-level action of a remarkable class of ring-shape... with the Lawrence Berkeley National Laboratory (B...tallography beamline at the Advanced Light Source ...gene expression and replication, and are vital to ...nfectious agents, such as the human papillomavirus...
(Date:11/24/2009)...stitutes fish food is a matter of debate. A high-p...et almost 50 percent of their carbon from trees an...he terrestrial and aquatic ecosystems. , But new...this is not likely to be true. Algae provide a muc...ording to research published this week in the Pro...
(Date:11/23/2009)...n, D.C. The community-associated strain of the de...sistant to most common antibioticsposes a far grea...ing its way into hospitals, according to a study i...ses . , The new threat is easily picked up in f...nd has increased the overall burden of MRSA within...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2pMDsoft Announces Interfaces with Additional EMR EHR Practice Management Hospital and Billing Systems 56507 1pMDsoft Announces Interfaces with Additional EMR EHR Practice Management Hospital and Billing Systems 56507 2pMDsoft Announces Interfaces with Additional EMR EHR Practice Management Hospital and Billing Systems 56507 3pMDsoft Announces Interfaces with Additional EMR EHR Practice Management Hospital and Billing Systems 56507 4pMDsoft Announces Interfaces with Additional EMR EHR Practice Management Hospital and Billing Systems 56507 5realbuzz com Top 25 Things to do Before You Die 56505 1realbuzz com Top 25 Things to do Before You Die 56505 2Details of DNC Fall Meeting in Austin 56503 1Details of DNC Fall Meeting in Austin 56503 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |